WEBSITE BSE:526953 NSE: VENUS REMEDI Inc. Year: 1989 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 14:09
No Notes Added Yet
Venus Remedies Ltd is engaged in pharmaceutical product production enterprise. The Company offers formulations and manufactures dosage injectables. The Company is engaged in production and trading of medicines. It makes a speciality of critical care and speciality segment, consisting of anti-infective (anti-microbial resistance), anticancer, neurology, ache control, and pores and skin and wound care. The Company manufactures complicated formulations for oncology injections, oncology lyophilized, lyophilized injections, pre-crammed syringes and ...Read More
Venus Remedies Ltd is engaged in pharmaceutical product production enterprise. The Company offers formulations and manufactures dosage injectables. The Company is engaged in production and trading of medicines. It makes a speciality of critical care and speciality segment, consisting of anti-infective (anti-microbial resistance), anticancer, neurology, ache control, and pores and skin and wound care. The Company manufactures complicated formulations for oncology injections, oncology lyophilized, lyophilized injections, pre-crammed syringes and cephalosphorins, amongst others. It also manufactures numerous brands, together with Doxol, Paxol, Citabol, Epirol, Ronem, Immunox, Pimcef, Fejet, Parin-E, Vanconex, Supime, Tobracef, Vancoplus, Potentox, Septiloc, Acnano, Sulbactomax, Ampucare, Achnil, Meropenem and Pirotum amongst others. Its product portfolio contains of over seventy five merchandise in various therapeutic segments. The Company has over three production units in Panchkula, Baddi (India) and Werne (Germany). ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹1313 Cr.
Stock P/E 29
P/B 2.1
Current Price ₹982.3
Book Value ₹ 463.7
Face Value 10
52W High ₹1119
Dividend Yield 0%
52W Low ₹ 295
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 132 | 193 | 180 |
| Other Income | 3 | 2 | 4 | 2 | 8 | 2 | 7 | 9 | 2 | 3 |
| Total Income | 171 | 146 | 199 | 110 | 178 | 179 | 202 | 141 | 194 | 183 |
| Total Expenditure | 150 | 131 | 176 | 97 | 163 | 159 | 166 | 122 | 162 | 143 |
| Operating Profit | 21 | 14 | 23 | 13 | 15 | 20 | 36 | 19 | 33 | 40 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 |
| Provision for Tax | 4 | 1 | 7 | 6 | 6 | 5 | 10 | 3 | 6 | 8 |
| Profit After Tax | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 |
| Adjusted Earnings Per Share | 7.4 | 5.1 | 7.9 | 0.9 | 2.6 | 14.7 | 15.7 | 7.2 | 15.1 | 19.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 464 | 418 | 400 | 372 | 322 | 339 | 548 | 600 | 556 | 601 | 648 | 700 |
| Other Income | 1 | 2 | 4 | 2 | 6 | 5 | 20 | 8 | 10 | 12 | 21 | 21 |
| Total Income | 465 | 420 | 404 | 375 | 328 | 345 | 568 | 608 | 566 | 613 | 669 | 720 |
| Total Expenditure | 375 | 337 | 349 | 333 | 289 | 299 | 494 | 538 | 495 | 542 | 584 | 593 |
| Operating Profit | 90 | 83 | 55 | 42 | 39 | 46 | 73 | 70 | 70 | 71 | 84 | 128 |
| Interest | 41 | 38 | 36 | 36 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 24 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -9 | -9 | 23 | 0 | 0 | 0 | 10 | 0 |
| Profit Before Tax | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 103 |
| Provision for Tax | -3 | 2 | -5 | 3 | -1 | 2 | -13 | -4 | 11 | 16 | 27 | 27 |
| Profit After Tax | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 77 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 77 |
| Adjusted Earnings Per Share | 4.5 | 1.5 | -13.8 | -24.9 | -23.2 | -8.1 | 50 | 30.5 | 19.9 | 21.3 | 33.9 | 57.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 8% | 3% | 14% | 3% |
| Operating Profit CAGR | 18% | 6% | 13% | -1% |
| PAT CAGR | 61% | 3% | 0% | 25% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 218% | 72% | 24% | 27% |
| ROE Average | 9% | 7% | 10% | 2% |
| ROCE Average | 13% | 10% | 10% | 6% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 457 | 438 | 389 | 362 | 333 | 323 | 400 | 440 | 460 | 488 | 561 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 202 | 191 | 162 | 137 | 116 | 72 | 47 | 39 | 39 | 39 | 0 |
| Other Non-Current Liabilities | 19 | 21 | 18 | 21 | 21 | 24 | 11 | 7 | 19 | 21 | 18 |
| Total Current Liabilities | 163 | 193 | 197 | 230 | 264 | 225 | 97 | 93 | 83 | 79 | 136 |
| Total Liabilities | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 579 | 601 | 627 | 716 |
| Fixed Assets | 444 | 452 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 |
| Other Non-Current Assets | 164 | 113 | 99 | 101 | 103 | 60 | 60 | 60 | 62 | 49 | 35 |
| Total Current Assets | 233 | 277 | 259 | 260 | 265 | 294 | 234 | 278 | 323 | 360 | 452 |
| Total Assets | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 579 | 601 | 627 | 716 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 4 | 7 | 0 | 4 | 2 | 2 | 29 | 43 | 21 | 49 |
| Cash Flow from Operating Activities | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 |
| Cash Flow from Investing Activities | -67 | 3 | -18 | -11 | -11 | -5 | 56 | -17 | -51 | -7 | -76 |
| Cash Flow from Financing Activities | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | -1 |
| Net Cash Inflow / Outflow | -1 | 3 | -4 | -20 | -1 | -0 | 26 | 15 | -15 | 29 | 9 |
| Closing Cash & Cash Equivalent | 4 | 7 | 4 | -20 | 3 | 2 | 29 | 43 | 21 | 49 | 58 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.51 | 1.48 | -13.84 | -24.87 | -23.15 | -8.1 | 50.04 | 30.47 | 19.87 | 21.31 | 33.9 |
| CEPS(Rs) | 44.71 | 37.91 | 18.78 | 2.54 | 4.38 | 17.84 | 78.63 | 55.55 | 44.04 | 41.1 | 50.74 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 399.13 | 382.47 | 314.92 | 293.23 | 269.42 | 262.01 | 313.18 | 329.5 | 344.38 | 364.74 | 419.65 |
| Core EBITDA Margin(%) | 19.22 | 19.4 | 12.68 | 10.6 | 10.1 | 12.03 | 9.81 | 10.35 | 10.81 | 9.91 | 9.81 |
| EBIT Margin(%) | 9.45 | 9.92 | 3.68 | 2.16 | -1.34 | 1.56 | 11.23 | 6.15 | 6.85 | 7.44 | 11.1 |
| Pre Tax Margin(%) | 0.57 | 0.84 | -5.41 | -7.39 | -9.23 | -2.37 | 8.86 | 6.07 | 6.83 | 7.42 | 11.09 |
| PAT Margin (%) | 1.11 | 0.41 | -4.27 | -8.24 | -8.88 | -2.95 | 11.27 | 6.79 | 4.78 | 4.74 | 6.99 |
| Cash Profit Margin (%) | 11.03 | 10.37 | 5.79 | 0.84 | 1.68 | 6.49 | 17.7 | 12.37 | 10.6 | 9.13 | 10.47 |
| ROA(%) | 0.62 | 0.2 | -2.12 | -4.05 | -3.85 | -1.45 | 10.3 | 7.18 | 4.5 | 4.64 | 6.75 |
| ROE(%) | 1.12 | 0.38 | -4.13 | -8.18 | -8.23 | -3.05 | 17.4 | 9.85 | 5.9 | 6.01 | 8.64 |
| ROCE(%) | 5.74 | 5.35 | 2 | 1.17 | -0.67 | 0.9 | 12.37 | 7.89 | 7.72 | 8.67 | 13.17 |
| Receivable days | 50.42 | 54.45 | 49.67 | 46.34 | 48.37 | 36.97 | 20.89 | 21.48 | 37.87 | 47.69 | 54.28 |
| Inventory Days | 112.15 | 124.86 | 129.51 | 136.61 | 159.26 | 152.66 | 86.94 | 74.69 | 80.68 | 73.32 | 62.59 |
| Payable days | 41.25 | 41.86 | 44.1 | 52.56 | 65.53 | 76.11 | 57.86 | 57.31 | 55.69 | 53.52 | 69.91 |
| PER(x) | 29.55 | 59.61 | 0 | 0 | 0 | 0 | 5.49 | 8.82 | 8.15 | 15.31 | 8.84 |
| Price/Book(x) | 0.33 | 0.23 | 0.31 | 0.22 | 0.12 | 0.09 | 0.88 | 0.82 | 0.47 | 0.89 | 0.71 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.01 | 1.03 | 1.07 | 1.03 | 1.04 | 0.73 | 0.65 | 0.59 | 0.37 | 0.68 | 0.5 |
| EV/Core EBITDA(x) | 5.23 | 5.16 | 7.8 | 9.17 | 8.7 | 5.34 | 4.89 | 5 | 2.9 | 5.75 | 3.81 |
| Net Sales Growth(%) | -14.32 | -9.85 | -4.36 | -6.91 | -13.57 | 5.42 | 61.53 | 9.5 | -7.44 | 8.27 | 7.72 |
| EBIT Growth(%) | -55.46 | -5.41 | -64.47 | -45.53 | -153.82 | 222.71 | 1061.31 | -40.09 | 3.14 | 17.58 | 60.7 |
| PAT Growth(%) | -91.97 | -67.08 | -1105.46 | -79.69 | 6.9 | 65.01 | 717.7 | -34.07 | -34.77 | 7.25 | 59.05 |
| EPS Growth(%) | -91.97 | -67.08 | -1032.14 | -79.69 | 6.9 | 65.01 | 717.7 | -39.12 | -34.77 | 7.25 | 59.05 |
| Debt/Equity(x) | 0.7 | 0.77 | 0.8 | 0.85 | 0.9 | 0.68 | 0.13 | 0.1 | 0.09 | 0.08 | 0 |
| Current Ratio(x) | 1.43 | 1.43 | 1.32 | 1.13 | 1.01 | 1.31 | 2.4 | 3 | 3.91 | 4.53 | 3.31 |
| Quick Ratio(x) | 0.55 | 0.69 | 0.6 | 0.53 | 0.47 | 0.68 | 1.17 | 1.64 | 2.46 | 2.99 | 2.58 |
| Interest Cover(x) | 1.06 | 1.09 | 0.41 | 0.23 | -0.17 | 0.4 | 4.73 | 76.69 | 322.44 | 477.45 | 1099.26 |
| Total Debt/Mcap(x) | 2.1 | 3.31 | 2.58 | 3.79 | 7.28 | 7.94 | 0.15 | 0.12 | 0.2 | 0.09 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 | 41.76 |
| FII | 1.59 | 1.48 | 1.06 | 1.18 | 1.11 | 1.34 | 2.24 | 1.86 | 2.26 | 2.8 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0.11 | 0.75 | 1.03 | 1.2 |
| Public | 56.65 | 56.76 | 57.18 | 57.06 | 57.13 | 56.9 | 55.89 | 55.63 | 54.96 | 54.24 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 | 0.56 |
| FII | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.02 |
| Public | 0.76 | 0.76 | 0.76 | 0.76 | 0.76 | 0.76 | 0.75 | 0.74 | 0.73 | 0.73 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
